The immune profile of sarcomatoid renal cell carcinoma (sRCC), including the programmed cell death ligand 1 (PD-L1) and programmed cell death 1 (PD-1) status, has not been well characterized. METHODS: An immunohistochemical digital analysis of PD-L1, PD-1, CD4, and CD8 was performed on nephrectomy specimens from 118 sRCC patients and 92 nonsarcomatoid clear cell renal cell carcinoma (ccRCC) patients. The clinical characteristics of the population were compared between sRCC and ccRCC. Overall survival was estimated, and comparisons were made between PD-L1-positive and PD-L1-negative groups as well as tumorinfiltrating lymphocyte (TIL)-high and TIL-low groups. RESULTS: The PD-L1 H-score of sRCC (mean, 3.7; range, 0-192.1) was significantly higher than the score of grade 4 ccRCC (P 5.001), and 41.3% of sRCC cases showed a PD-L1 H-score 10. The PD-1-positive cell density was significantly higher in sRCC versus ccRCC within the tumor and at the invasive front. The intratumoral CD8-positive cell density was significantly higher in sRCC versus ccRCC. Forty-one percent in the sarcomatoid component of sRCC and 8% in the epithelioid component of sRCC had an adaptive immune resistance phenotype (PD-L1-positive and TIL-positive), whereas only 1% in ccRCC had the type I phenotype. CONCLUSIONS: sRCC showed higher PD-L1 expression and higher PD-1-and CD8-positive cell density than grade 4 ccRCC. The results indicate a notable immunosuppressive environment in sRCC. Despite advances in the treatment of advanced-stage renal cell carcinoma, sRCC still has a poor prognosis. This work describes highly immunosuppressive characteristics of sRCC in comparison with an appropriate ccRCC control. The results suggest PD-1/PD-L1 blockade therapy as a potential therapeutic approach for sRCC. Cancer 2017;123:4823-31.
INTRODUCTION
Although the advent of targeted therapies has significantly improved survival for patients with metastatic renal cell carcinoma (RCC) in the past decade, the efficacy of these new drugs is limited in patients with sarcomatoid renal cell carcinoma (sRCC) because these patients experience the worst outcomes of all patients with RCC. [1] [2] [3] Programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) are promising targets for novel immunotherapeutic approaches, and their marker status carries potential prognostic value in clear cell renal cell carcinoma (ccRCC). 4, 5 Previous work has identified a robust ccRCC subtype with overexpression of genes related to the immune response, including high expression of PD-1, PD-L1, and programmed cell death ligand 2 (PD-L2), that frequently shows sarcomatoid dedifferentiation and inflammation histologically. 6 In addition, PD-L1 induces the epithelial-mesenchymal transition in RCC, 7 and sRCC is considered a good example of the epithelial-mesenchymal transition both morphologically and immunohistochemically. 8 Two studies evaluated PD-L1 expression in sRCC with a clear cell epithelioid component (clear cell sarcomatoid renal cell carcinoma [cc-sRCC]) and found it to be significantly higher in comparison with nonsarcomatoid ccRCC. 9, 10 Furthermore, 50% of sRCCs showed co-expression of PD-1/PD-L1, whereas only 3% of nonsarcomatoid ccRCCs showed PD-1/PD-L1 co-expression. 9 Therefore, sRCC may represent a promising disease subset for immune checkpoint blockade therapy. However, because of the rarity of sRCC, these tissue-based studies have been small, and PD-1 and PD-L1 expression in sRCC has not been adequately compared with their expression in high-grade nonsarcomatoid RCC.
Our study objectives were 1) to examine PD-L1 expression as well as the tumor-infiltrating lymphocyte (TIL) status, including PD-1 expression, in a large series of patients with sRCC and 2) to compare the marker status for sRCC (sarcomatoid and epithelioid components), nonsarcomatoid ccRCC, and subtypes of sRCC, including cc-sRCC and non-clear cell sarcomatoid renal cell carcinoma (non-cc-sRCC; sarcomatoid and epithelioid components).
MATERIALS AND METHODS

Patient and Sample Data Collection
We identified 118 patients with sRCC who were treated surgically at The University of Texas MD Anderson Cancer Center from 2000 through 2012. Patients who received neoadjuvant therapy (n 5 21) and cases with digital analysis failure (n 5 3) were excluded from the study. The total number of patients with sRCC included in this study was 94. An additional cohort of 92 patients with nonsarcomatoid ccRCC, including 20 patients with grade 4 disease, 58 patients with grade 3 disease, and 14 patients with grade 2 disease, was evaluated for comparison. The study design is illustrated in Supporting Figure 1 (see online supporting information). This study was approved by the institutional review board at The University of Texas MD Anderson Cancer Center.
Formalin-fixed, paraffin-embedded blocks from all cases were retrieved from the pathology department, and all hematoxylin-eosin (H & E) tumor slides from all cases were re-reviewed by 2 dedicated genitourinary pathologists (K.S. and F.K.) to confirm the diagnosis of sRCC and to document the histology of the epithelioid component, the highest Fuhrman nuclear grade of the epithelioid component, and the percentage of the sarcomatoid component. All H & E tumor slides were used to evaluate these parameters. Baseline clinicopathologic characteristics, including the age at the time of surgery, sex, tumor size at the time of surgery, and TNM stage at the time of surgery, and follow-up data were retrospectively collected from the patients' medical records (Table 1) .
Whole-Section Cutting and Tissue Microarray (TMA) Construction After a review of all H & E tumor slides, a representative slide and the corresponding tumor block were selected for each patient and for the control nonsarcomatoid ccRCC cohort. If there was no block containing both sarcomatoid and epithelioid components, we selected 2 blocks for 1 case for each sarcomatoid and epithelioid component. On the representative slide that included the area of the sarcomatoid or epithelioid component, 3 areas of tumor tissue were marked by a pathologist (F.K.). From the corresponding paraffin block, five 4-lm-thick sections were cut for each sample. Then, TMAs were constructed via the sampling of 3 cores of a 1-mm diameter for each component. The cores were arranged as a 90-core format array in a new paraffin block. TMAs were constructed with the VTA-100 semi-automated tissue arrayer (Veridiam, Oceanside, California). All 94 sRCCs and 86 ccRCCs (20 at grade 4, 57 at grade 3, and 9 at grade 2) were included in the TMA blocks.
Immunohistochemical Analysis
An immunohistochemical analysis for the expression of PD-L1 (E1L3N; 1:100 dilution; Cell Signaling Technology, Danvers, Massachusetts), PD-1 (EPR4877(2); 1:250 dilution; Epitomics, Burlingame, CA), CD4 (4B12; 1:80 dilution; Leica Biosystems, Wetzlar, Germany), and CD8 (C8/144B; 1:25 dilution; Thermo Fisher Scientific, Waltham, Massachusetts) was performed. Sections were stained with primary antibodies on a BOND-MAX stainer (Leica Biosystems). The immunohistochemical reaction was detected with the Leica Bond Polymer Refine Detection kit (Leica Biosystems), and 3,3 0 -diaminobenzidine was Fig. 1 ). The mean H-score of the 5 areas was calculated for each case, and the mean H-scores were calculated separately for the epithelioid and sarcomatoid components of sRCC. Two pathologists (F.K. and K.S.) manually evaluated PD-L1 tumor positivity, which was defined as 5% tumor cell membrane staining independently, as a quality control measure. 9, 10 Cases in which the H-score differed from the results of the manual evaluation because of diffuse infiltration of PD-L1-stained immune and endothelial cells in the tumor area and cytoplasmic PD-L1 staining of tumor cells were excluded from the study. For PD-L1 immunohistochemistry, among the 94 sRCC cases, digital immunohistochemical analysis was possible in both the sarcomatoid and epithelioid components in only 84 cases (66 cc-sRCC cases and 18 non-cc-sRCC cases). PD-L1 expression in either the epithelioid or sarcomatoid component, but not both, was calculated for the remaining 10 cases.
Five 1-mm 2 areas within the intratumoral region and within the peritumoral region from the sarcomatoid and epithelioid components from each case were individually chosen by a pathologist (F.K.) for PD-1 digital analysis. A histology assessment of each 1-mm 2 area was performed to ensure that tumor tissue presented in the selected intratumoral region and that only nonmalignant cells were included in the peritumoral region, as previously described. 11 The mean number of PD-1-positive immune cells per 1 mm 2 within the intratumoral region and within the peritumoral region was calculated for the sarcomatoid and epithelioid components separately. The intratumoral region could be evaluated in 92 cases for the sarcomatoid component and in 86 cases for the epithelioid component of sRCC, whereas the peritumoral region could be evaluated in approximately half of the candidate cases (51 in the sarcomatoid component and 54 in the epithelioid component of sRCC).
For the CD4 and CD8 evaluation, TMA was scored as the number of positive cells per 1-mm 2 and the mean number of positive cells of all cores from each case was calculated.
Tumor microenvironment categorization was performed on the basis of the density of TILs and the expression of PD-L1 12 : type I (adaptive immune resistance), type II (immunological ignorance), type III (intrinsic induction), and type IV (tolerance). Tumor PD-L1 expression (an H-score 10 was considered positive) was combined with the density of cells expressing CD4 or 
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Statistical Analysis
The clinical characteristics of the population were compared between epithelioid and sarcomatoid components with the Kruskal-Wallis test. The Wilcoxon signed-rank test was conducted for comparing epithelioid and sarcomatoid components on the basis of PD-L1 expression and the number of PD-1-positive (intratumoral region and peritumoral region), CD4-positive, and CD8-positive lymphocytes. Overall survival was defined as the time from surgery to death. In the absence of an event, endpoints were censored at the last follow-up time. Overall survival was estimated with the Kaplan-Meier productlimit estimator and was compared between PD-L1-positive and PD-L1-negative groups. The correlations between lymphocyte infiltration and PD-L1 expression, lymphocyte infiltration and PD-1 expression, and PD-L1 and PD-1 expression were assessed with Spearman correlation coefficients (ie, Spearman's q).
An analysis-of-variance model was created to determine whether there was a difference in expression levels between clear cell groups (epithelioid, sarcomatoid, grade 2, grade 3, and grade 4). If the analysis of variance indicated a difference between these groups, a Tukey-Kramer pairwise comparison test was conducted to determine which groups differed. A P value (2-sided) < .05 was considered statistically significant.
The analysis was performed with SPSS Statistics 24 (IBM Corp., Armonk, New York). Scatter diagrams were drawn with GraphPad Prism 6 (GraphPad Software, Inc, La Jolla, California).
The Cancer Genome Atlas (TCGA) Data Analysis
We studied the alterations of CD274 (PD-L1) and genes that were related to antigen presentation (human leukocyte antigen A [HLA-A], HLA-B, HLA-C, HLA-G, HLA-DPB1, and TAP1) and T cell-mediated immunity (CD3D, CD8A, IL2RA, IL7R, IDO1, CD4, CD27, CD28, CCL5, and CCR5) as well as reported genes that are frequently altered in sRCC (TP53, PTEN, RELN, CDKN2A, and NF2) in the Kidney Renal Clear Cell Carcinoma (TCGA, Nature 2013) case set with cBioPortal (http:// cbioportal.org). The frequency of genomic alteration events (including mutations), putative copy-number alterations from GISTIC, messenger RNA (mRNA) expression z scores (RNA-Seq version 2; RNA sequencing by expectation-maximization) with z-score thresholds (62.0), and protein expression (reverse-phase protein array) with zscore thresholds (62.0) were evaluated in the 469 patients with mRNA data (RNA-Seq version 2).
RESULTS
Patient Characteristics
Of the 118 patients with sRCC, 21 who received neoadjuvant therapy and 3 whose digitally calculated H-scores differed from manual evaluation results were excluded from the study, and this left 94 patients with sRCC for analysis (Supporting Fig. 1 [see online supporting information] ). Patient characteristics are summarized in Table 1 . The median tumor diameter was 10.8 cm (range, 1.1-27 cm). Seventy-four cases (78.7%) were cc-sRCC (Supporting Table 1 [see online supporting information]). The median follow-up time of the cohort was 11 months (interquartile range, 7-27 months). Seventy-six patients (80.9%) died of their disease during the follow-up period. The median follow-up time for survivors was 48 months (interquartile range, 21-107 months).
PD-L1 Expression and Survival in sRCC Overall
Among the sRCC cases, the median H-score for PD-L1 expression was significantly higher in the sarcomatoid component (3.7; range, 0-192.1) versus the epithelioid component (0.2; range, 0-222.0; P < .001; Table 2 ).
In the sarcomatoid component of sRCC, a higher PD-L1 H-score was associated with a younger age (<60 years) at the time of surgery (P 5 .033) but not with sex, TNM classification, disease stage, tumor size, or percentage of the sarcomatoid component (Table 2) .
A survival analysis based on the PD-L1 expression H-score was performed for 92 sRCC patients with at least 1 year of clinical follow-up (or less in the case of death). All sRCC cases with PD-L1 positivity on the manual evaluation showed an H-score 10. With this threshold, 41.3% of the sRCC cases were PD-L1-positive, and there was no significant survival difference between the PD-L1-positive and PD-L1-negative groups (P 5 .385; Fig. 2 ).
PD-L1 Expression in cc-sRCC and Nonsarcomatoid ccRCC
Among the cc-sRCC cases (n 5 74), the median PD-L1 H-score in the sarcomatoid component (1.8; range, 0-192.1) was significantly higher than that in the epithelioid component (0.2; range, 0-222.0; P < .001; Table 2 ). In 43.2% of cc-sRCC cases, the PD-L1 H-score was 10 in at least 1 of these components.
In the nonsarcomatoid ccRCC cases (controls), the PD-L1 H-scores for grade 4, 3, and 2 ccRCCs were Original Article significantly lower than the score for the sarcomatoid component of cc-sRCC (P 5 .001; Table 2 and Fig. 3) , and only 2.2% of ccRCCs were PD-L1-positive (10% of grade 4, 0% of grade 3, and 0% of grade 2).
PD-L1 Expression in Non-cc-sRCC
Among the 20 non-cc-sRCC cases, 11 (55.0%) showed PD-L1 H-scores 10; they included 3 of 5 chromophobe sRCCs, 5 of 10 papillary sRCCs, and 3 of 3 collecting duct sRCCs.
The median PD-L1 H-score of the sarcomatoid component of non-cc-sRCC was 5.7 (range, 0.1-151.4), whereas that of the epithelioid component was 1.2 (range, 0-129.0). Although the median H-score of the sarcomatoid component of non-cc-sRCC was higher than that of the epithelioid component, the difference was not statistically significant (P 5 .058), likely because of the small patient numbers in this subgroup (Table 2) .
PD-1-Positive Cell Density in sRCC and Nonsarcomatoid ccRCC in the Intratumoral Region and Peritumoral Region
We found that the PD-1-positive cell density was significantly higher in sRCC than nonsarcomatoid ccRCC within the intratumoral region and peritumoral region ( Table 3 ). The sarcomatoid component contained a significantly higher density of PD-1-positive cells than the epithelioid component in the intratumoral region (P 5 .039), and cc-sRCC contained a significantly higher density of PD-1-positive cells within the tumor and peritumoral region than did grade 4 nonsarcomatoid ccRCC (Table 3 ). There was no significant difference in survival between cases with a high density of PD-1-positive cells (PD-1 density higher than the median PD-1 density of sRCCs) and those with a low density of PD-1-positive cells (PD-1 density lower than or equal to the median PD-1 density of sRCCs) in either the peritumoral region or the intratumoral region in the multivariate analysis (Supporting Table 2 [see online supporting information]). Table 2 [see online supporting information]). Combining PD-L1 expression in tumor cells with the density of TILs (the density of CD4-positive or CD8-positive cells), as proposed by Teng et al, 12 we classified patients into the 4 subtypes of tumor microenvironment (Supporting Table 3 [see online supporting information). This analysis showed that 41% in the sarcomatoid component of sRCC and 8% in the epithelioid component of sRCC had an adaptive immune resistance phenotype (type I), whereas only 1% in nonsarcomatoid ccRCC had the type I phenotype. The pattern most frequently observed (sarcomatoid component of sRCC, 41%; epithelioid component of sRCC, 55%; and nonsarcomatoid ccRCC, 54%) was that of tumors with the immune tolerance pattern (type IV), which was defined as positive TILs without PD-L1 expression in tumor cells. Cases with negative PD-L1 expression and negative TILs, defined as tumors with the immunological ignorance pattern (type II), were found in the sarcomatoid component of sRCC (17%), the epithelioid component of sRCC (35%), and nonsarcomatoid ccRCC (44%). Tumors with the intrinsic induction pattern (type III; positive PD-L1 expression and negative TILs) were less frequently detected (sarcomatoid component of sRCC, 1%; epithelioid component of sRCC, 2%; and nonsarcomatoid ccRCC, 1%).
TCGA Data Analysis
mRNA CD274 upregulation was significantly correlated with mRNA upregulation of some genes related to antigen presentation (P for HLA-B 5 .026, P for HLA-DPB1 < .001, and P for TAP1 < .001) and a chemokine receptor (P for CCR5 < .001). There was no significant correlation between mRNA upregulation of CD274 and gene alteration, which was previously described in sRCC (Supporting Fig. 3 [see online supporting information]).
DISCUSSION
In this large tissue-based cohort study of surgically resected sRCC, we found that sRCC was more frequently positive for PD-L1 than nonsarcomatoid ccRCC. Although sRCC is defined as grade 4 RCC, PD-L1 expression was even higher in cc-sRCC versus nonsarcomatoid grade 4 ccRCC. Furthermore, sRCC was associated with a more pronounced cytotoxic T-cell infiltrate and adaptive immune resistance phenotype in its major tumor microenvironment according to the PD-L1 expression and TIL status. These data suggest that cc-sRCC is distinct from nonsarcomatoid ccRCC at the level of immune markers with an inflammatory histology. This could indicate the biological distinctiveness of sRCC and could have potential therapeutic implications.
Two recent reports studied PD-1 and PD-L1 expression in sRCC. Joseph et al 9 collected 26 sRCCs and 29 nonsarcomatoid ccRCCs, performed an immunohistochemical analysis for PD-1 and PD-L1 in whole sections, and found increased expression of PD-L1 on tumor cells (54% of sRCCs and 17% of nonsarcomatoid ccRCCs; P 5 .006) concurrent with PD-1-positive TILs in sRCC (96% of sRCCs and 62% of nonsarcomatoid ccRCCs; P 5 .003). For sRCC cases, the authors evaluated only the sarcomatoid component. Shin et al 10 collected 54 ccsRCCs and 9 papillary sRCCs as well as nonsarcomatoid RCCs and evaluated their PD-L1, PD-L2, and PD-1 expression with a TMA. They reported that PD-L1 positivity was significantly higher in cc-sRCCs (29.6% of sRCCs and 7.3% of nonsarcomatoid ccRCCs; P < .001) but not in papillary RCCs. They did not note which component (sarcomatoid or epithelioid) of sRCC was evaluated. The limitations of these 2 prior studies are their relatively small case numbers and the inadequacy of the control cases. In both studies, the sarcomatoid and epithelioid components in sRCC were not separately evaluated. In addition, the control cases were not stratified by histologic grade. Because previous reports suggested that higher PD-L1 expression in the tumor cell membrane was correlated with a higher Fuhrman grade, 4, 13, 14 we believe that it is important to compare the immune checkpoint marker status between sRCC and high-grade nonsarcomatoid ccRCC specifically. As for the immunohistochemical evaluation methodologies, both studies counted tumor cytoplasmic stains of PD-L1 as positive. Reported clinical trials generally have defined tumor membranous staining 5% as PD-L1-positive. 15, 16 Thus, the 2 previous reports might have overestimated the PD-L1-positive rate.
RCC is an immunogenic tumor, and prior literature suggests that the presence of specific T-lymphocyte subsets in RCC could be associated with a prognostic value. For example, patients with CD45RO-positive, T cellrich RCC showed shorter overall survival than patients with CD45RO-positive, T cell-poor RCC. 17 Although high intratumoral CD4-positive T-cell infiltration and both higher peripheral blood regulatory T-cell counts and high intratumoral Foxp3-positive regulatory T-cell infiltration have been associated with a poor prognosis in RCC, [17] [18] [19] [20] the role of CD8-positive T cells in RCC is still controversial. Some studies have shown that CD8-positive T-cell infiltration in RCC has no survival impact, 17 and other reports have shown that CD8-positive, T cell-rich RCC is associated with poor survival 21, 22 ; however, in one study, 23 a CD8-positive, T cell-rich phenotype was observed in the renal tumors of long-surviving patients. 23 There are also a few reports describing the relation between PD-L1 expression in RCC tumor cells and TIL fractionation. A higher level of tumor PD-L1 expression has been associated with low relative ratios of CD8-positive T cells to Foxp3-positive T cells in metastatic RCC. 24 In this study, we studied TIL markers in sRCC and found an inflammatory infiltrate-rich histology with PD-L1 expression. We found more frequent PD-1 and 12 in comparison with their epithelioid component, ccRCC cases, and other reported tumor types such as non-small cell lung cancer 11 and melanoma. 25 The tumors with a type I tumor microenvironment are thought to be the group that largely responds to immune checkpoint blockade 25, 26 and are most likely to benefit from single-agent anti-PD-1/PD-L1 blockade because these tumors have evidence of preexisting intratumoral T cells that are turned off by PD-L1 engagement.
Our current study is different from prior studies on this topic because it has a larger number of sRCC cases and, more importantly, adequate nonsarcomatoid ccRCC controls. Specifically, we describe the difference in the PD-L1 expression status between cc-sRCC and grade 4 nonsarcomatoid ccRCC, which we believe to be the most adequate control group (because both are grade 4). Our study is also significant because we evaluated epithelioid and sarcomatoid components separately, and we found that PD-1/PD-L1 expression in the epithelioid component of sRCC was significantly higher than that in grade 4 nonsarcomatoid ccRCC. Because the median amount of the sarcomatoid component in sRCC tumors is 40% to 50% and so might not be sampled by the biopsying of a patient with sRCC, our finding is essential to know before one considers assaying for the PD-L1/PD-1 status on the basis of biopsy specimens. There may be intratumoral heterogeneity in addition to morphologic diversity. Furthermore, our results show a difference in the immune marker status between sRCC and nonsarcomatoid grade 4 ccRCC, and this indicates that cc-sRCC is distinct from nonsarcomatoid ccRCC at the level of immune markers. These data indicate the biological distinctiveness of sRCC and have potential therapeutic implications for novel immune therapy. This study is also methodologically distinctive because the immunohistochemical results not only were digitally analyzed to secure high reproducibility and quantification but also were concurrently confirmed with manual evaluations with a standard positivity threshold of 5% tumor membranous expression.
The limitation of this study is its lack of gene expression data. It would be interesting to study whether PD-L1 protein expression in sRCC is correlated with the expression of CD274 (PD-L1) mRNA and genes related to antigen presentation and T cell-mediated immunity as well as a gene signature that may be linked to sarcomatoid features. TCGA data revealed that mRNA CD274 upregulation was significantly correlated with mRNA upregulation of HLA genes and a chemokine receptor, and this suggests a close link between the upregulation of PD-L1 and the inflammatory tumor microenvironment in ccRCC. Although we could not find any significant correlation between the mRNA upregulation of CD274 and gene alteration, which was previously described in sRCC, 27, 28 TCGA is not the ideal setting for studying sRCC and contains only a few sRCC cases. In addition, data on sRCC in TCGA were obtained only from the epithelioid component. Further molecular-protein expression correlation studies are needed in sRCC.
In conclusion, sRCC is more frequently positive for PD-L1 and shows higher PD-L1 expression than nonsarcomatoid ccRCC, regardless of its epithelioid component histology. cc-sRCC shows a higher frequency and stronger expression of PD-L1 than nonsarcomatoid grade 4 ccRCC. Because a large part of sRCC carries an adaptive immune resistance tumor microenvironment, checkpoint blockade could be a particularly promising therapeutic agent for sRCC.
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